These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27373582)

  • 41. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
    Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
    Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening.
    Clark EM; Carter L; Gould VC; Morrison L; Tobias JH
    Osteoporos Int; 2014 Mar; 25(3):953-64. PubMed ID: 24292107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
    O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
    Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of UK National Guidelines based on FRAX®--comparison with current clinical practice.
    Crabtree NJ; Bebbington NA; Chapman DM; Wahid YS; Ayuk J; Boivin CM; Cooper MS; Gittoes NJ;
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):452-6. PubMed ID: 20626412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2018 update of French recommendations on the management of postmenopausal osteoporosis.
    Briot K; Roux C; Thomas T; Blain H; Buchon D; Chapurlat R; Debiais F; Feron JM; Gauvain JB; Guggenbuhl P; Legrand E; Lehr-Drylewicz AM; Lespessailles E; Tremollieres F; Weryha G; Cortet B
    Joint Bone Spine; 2018 Oct; 85(5):519-530. PubMed ID: 29654947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
    Kanis JA; Cooper C; Rizzoli R; Reginster JY;
    Aging Clin Exp Res; 2019 Jan; 31(1):15-17. PubMed ID: 30612282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia.
    Pueyo MJ; Larrosa M; Surís X; Garcia-Ruiz AJ
    Reumatol Clin; 2012; 8(3):128-34. PubMed ID: 22421456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example.
    Ström O; Borgström F; Kleman M; McCloskey E; Odén A; Johansson H; Kanis JA
    Bone; 2010 Aug; 47(2):430-7. PubMed ID: 20493983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postmenopausal osteoporosis: fracture risk and prevention.
    Kaunitz AM; McClung MR; Feldman RG; Wysocki S
    J Fam Pract; 2009 Nov; 58(11 Suppl Postmenopausal):S1-6. PubMed ID: 19891943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
    Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
    Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the NOF and NOGG guidelines for spinal radiographic examination in postmenopausal Chinese women.
    Chen R; Liu S; Huang M; Ding N; Wang Q; Xie Z; Liu H; Sheng Z; Ou Y
    Arch Osteoporos; 2021 Jan; 16(1):5. PubMed ID: 33399996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland.
    Badurski JE; Kanis JA; Johansson H; Dobreńko A; Nowak NA; Daniluk S; Jezienicka E
    Pol Arch Med Wewn; 2011 May; 121(5):148-55. PubMed ID: 21610662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
    Silverman SL; Komm BS; Mirkin S
    Maturitas; 2014 Nov; 79(3):241-7. PubMed ID: 25124532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The activity of a Spanish bone densitometry unit revisited under the point of view of FRAX.
    Gómez-Vaquero C; Bianchi M; Santo P; Roig-Vilaseca D; Narváez J; Nolla JM
    Reumatol Clin; 2012; 8(4):179-83. PubMed ID: 22608955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study.
    Cipriani C; Pepe J; Bertoldo F; Bianchi G; Cantatore FP; Corrado A; Di Stefano M; Frediani B; Gatti D; Giustina A; Porcelli T; Isaia G; Rossini M; Nieddu L; Minisola S; Girasole G; Pedrazzoni M
    J Endocrinol Invest; 2018 Apr; 41(4):431-438. PubMed ID: 28956296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Osteoporosis in menopausal women between 40 and 65 years old : an algorithm for the gynaecologist].
    Surbone A; Vulliemoz N; Gonzalez-Rodriguez E; Chatelain JP; Lamy O
    Rev Med Suisse; 2016 Oct; 12(536):1811-1815. PubMed ID: 28692232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
    Hernandez I; Zhang Y
    J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Boonen A; Dirksen CD; Ben Sedrine W; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):19-28. PubMed ID: 23402442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effective osteoporosis intervention thresholds for Hong Kong postmenopausal women.
    Kung AW; McGhee SM; Tsang SW; So J; Chau J
    Hong Kong Med J; 2015 Dec; 21 Suppl 6():13-6. PubMed ID: 26645876
    [No Abstract]   [Full Text] [Related]  

  • 60. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.